首页> 美国卫生研究院文献>Nucleic Acids Research >Development of aptamer-based inhibitors for CRISPR/Cas system
【2h】

Development of aptamer-based inhibitors for CRISPR/Cas system

机译:基于Aptamer的CRISPR / CAS系统的抑制剂的发展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The occurrence of accidental mutations or deletions caused by genome editing with CRISPR/Cas9 system remains a critical unsolved problem of the technology. Blocking excess or prolonged Cas9 activity in cells is considered as one means of solving this problem. Here, we report the development of an inhibitory DNA aptamer against Cas9 by means of in vitro selection (systematic evolution of ligands by exponential enrichment) and subsequent screening with an in vitro cleavage assay. The inhibitory aptamer could bind to Cas9 at low nanomolar affinity and partially form a duplex with CRISPR RNA, contributing to its inhibitory activity. We also demonstrated that improving the inhibitory aptamer with locked nucleic acids efficiently suppressed Cas9-directed genome editing in cells and reduced off-target genome editing. The findings presented here might enable the development of safer and controllable genome editing for biomedical research and gene therapy.
机译:由CRISPR / CAS9系统的基因组编辑引起的意外突变或缺失的发生仍然是该技术的关键未解决问题。在细胞中阻断过量或长期Cas9活性被认为是解决这个问题的一种方法。在这里,我们通过体外选择(通过指数富集的配体的系统演化)和随后用体外切割测定进行筛选来报告对CAS9的抑制性DNA适体的开发。抑制性适体可以在低纳米摩尔亲和力下与Cas9结合,并部分地形成与CRISPR RNA的双链体,有助于其抑制活性。我们还证明,用锁定的核酸改善抑制型型型型型置换体,有效地抑制了细胞中的Cas9定向的基因组编辑并减少了偏离靶基因组编辑。这里提出的结果可以实现生物医学研究和基因治疗的更安全和可控基因组编辑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号